Sgalla G, Biffi A, Richeldi L (2016) Idiopathic pulmonary fibrosis: diagnosis, epidemiology and natural history. Respirology 21(3):427–437. https://doi.org/10.1111/resp.12683
Sharif R (2017) Overview of idiopathic pulmonary fibrosis (IPF) and evidence-based guidelines. Am J Manag Care 23(11 Suppl):S176–S182
Fernandez Perez ER, Daniels CE, Schroeder DR, St Sauver J, Hartman TE, Bartholmai BJ, Yi ES, Ryu JH (2010) Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest 137(1):129–137. https://doi.org/10.1378/chest.09-1002
Maher TM, Bendstrup E, Dron L, Langley J, Smith G, Khalid JM, Patel H, Kreuter M (2021) Global incidence and prevalence of idiopathic pulmonary fibrosis. Respir Res 22(1):197. https://doi.org/10.1186/s12931-021-01791-z
Article PubMed PubMed Central Google Scholar
Lai CC, Wang CY, Lu HM, Chen L, Teng NC, Yan YH, Wang JY, Chang YT, Chao TT, Lin HI, Chen CR, Yu CJ, Wang JD (2012) Idiopathic pulmonary fibrosis in Taiwan - a population-based study. Respir Med 106(11):1566–1574. https://doi.org/10.1016/j.rmed.2012.07.012
Lee HE, Myong JP, Kim HR, Rhee CK, Yoon HK, Koo JW (2016) Incidence and prevalence of idiopathic interstitial pneumonia and idiopathic pulmonary fibrosis in Korea. Int J Tuberc Lung Dis 20(7):978–984. https://doi.org/10.5588/ijtld.16.0003
Kim SW, Myong JP, Yoon HK, Koo JW, Kwon SS, Kim YH (2017) Health care burden and medical resource utilisation of idiopathic pulmonary fibrosis in Korea. Int J Tuberc Lung Dis 21(2):230–235. https://doi.org/10.5588/ijtld.16.0402
Article CAS PubMed Google Scholar
Varone F, Sgalla G, Iovene B, Bruni T, Richeldi L (2018) Nintedanib for the treatment of idiopathic pulmonary fibrosis. Expert Opin Pharmacother 19(2):167–175. https://doi.org/10.1080/14656566.2018.1425681
Article CAS PubMed Google Scholar
Lancaster LH, de Andrade JA, Zibrak JD, Padilla ML, Albera C, Nathan SD, Wijsenbeek MS, Stauffer JL, Kirchgaessler KU, Costabel U (2017) Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. Eur Respir Rev. https://doi.org/10.1183/16000617.0057-2017
Article PubMed PubMed Central Google Scholar
Fernandez IE, Eickelberg O (2012) The impact of TGF-beta on lung fibrosis: from targeting to biomarkers. Proc Am Thorac Soc 9(3):111–116. https://doi.org/10.1513/pats.201203-023AW
Article CAS PubMed Google Scholar
Hu HH, Chen DQ, Wang YN, Feng YL, Cao G, Vaziri ND, Zhao YY (2018) New insights into TGF-beta/Smad signaling in tissue fibrosis. Chem Biol Interact 292:76–83. https://doi.org/10.1016/j.cbi.2018.07.008
Article CAS PubMed Google Scholar
Fang Y, Tian J, Fan Y, Cao P (2020) Latest progress on the molecular mechanisms of idiopathic pulmonary fibrosis. Mol Biol Rep 47(12):9811–9820. https://doi.org/10.1007/s11033-020-06000-6
Article CAS PubMed Google Scholar
Ye Z, Hu Y (2021) TGFbeta1: gentlemanly orchestrator in idiopathic pulmonary fibrosis (Review). Int J Mol Med. https://doi.org/10.3892/ijmm.2021.4965
Article PubMed PubMed Central Google Scholar
Wu L, Li X, Li Z, Cheng Y, Wu F, Lv C, Zhang W, Tang W (2021) HtrA serine proteases in cancers: a target of interest for cancer therapy. Biomed Pharmacother 139:111603. https://doi.org/10.1016/j.biopha.2021.111603
Article CAS PubMed Google Scholar
Zhao J, Feng M, Liu D, Liu H, Shi M, Zhang J, Qu J (2019) Antagonism between HTRA3 and TGFbeta1 Contributes to Metastasis in Non-Small Cell Lung Cancer. Cancer Res 79(11):2853–2864. https://doi.org/10.1158/0008-5472.CAN-18-2507
Article CAS PubMed Google Scholar
Yin Y, Wu M, Nie G, Wang K, Wei J, Zhao M, Chen Q (2013) HtrA3 is negatively correlated with lymph node metastasis in invasive ductal breast cancer. Tumour Biol 34(6):3611–3617. https://doi.org/10.1007/s13277-013-0942-5
Article CAS PubMed Google Scholar
Forse CL, Rahimi M, Diamandis EP, Assarzadegan N, Dawson H, Grin A, Kennedy E, O’Connor B, Messenger DE, Riddell RH, Kirsch R, Karagiannis GS (2017) HtrA3 stromal expression is correlated with tumor budding in stage II colorectal cancer. Exp Mol Pathol 103(1):94–100. https://doi.org/10.1016/j.yexmp.2017.07.002
Article CAS PubMed Google Scholar
Sauleda J, Nunez B, Sala E, Soriano JB (2018) Idiopathic pulmonary fibrosis: epidemiology, natural history phenotypes. Med Sci (Basel). https://doi.org/10.3390/medsci6040110
Richeldi L, Rubin AS, Avdeev S, Udwadia ZF, Xu ZJ (2015) Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China. BMC Med. https://doi.org/10.1186/s12916-015-0495-0
Article PubMed PubMed Central Google Scholar
Chien J, Campioni M, Shridhar V, Baldi A (2009) HtrA serine proteases as potential therapeutic targets in cancer. Curr Cancer Drug Targets 9(4):451–468. https://doi.org/10.2174/156800909788486704
Article CAS PubMed PubMed Central Google Scholar
Zhao M, Ding JX, Nie GY, Wei J, Li Y, Yin XY, Chen Q (2014) HTRA3 is reduced in ovarian cancers regardless of stage. Cancer Invest 32(9):464–469. https://doi.org/10.3109/07357907.2014.958496
Article CAS PubMed Google Scholar
Lv Q, Yang B, Ning C, Xie B, Nie G, Chen X, Chen Q (2018) Hypoxia is involved in the reduction of HtrA3 in patients with endometrial hyperplasia and cancer. Biochem Biophys Res Commun 503(4):2918–2923. https://doi.org/10.1016/j.bbrc.2018.08.070
Article CAS PubMed Google Scholar
Tzouvelekis A, Gomatou G, Bouros E, Trigidou R, Tzilas V, Bouros D (2019) Common pathogenic mechanisms between idiopathic pulmonary fibrosis and lung cancer. Chest 156(2):383–391. https://doi.org/10.1016/j.chest.2019.04.114
Rogers TK (2004) Fibroblastic foci in usual interstitial pneumonia. Am J Respir Crit Care Med 169(5):654. https://doi.org/10.1164/ajrccm.169.5.950
Mori Y, Kondoh Y (2021) What parameters can be used to identify early idiopathic pulmonary fibrosis? Respir Investig 59(1):53–65. https://doi.org/10.1016/j.resinv.2020.10.008
Article CAS PubMed Google Scholar
Schiller HB, Fernandez IE, Burgstaller G, Schaab C, Scheltema RA, Schwarzmayr T, Strom TM, Eickelberg O, Mann M (2015) Time- and compartment-resolved proteome profiling of the extracellular niche in lung injury and repair. Mol Syst Biol 11(7):819. https://doi.org/10.15252/msb.20156123
Article CAS PubMed PubMed Central Google Scholar
Deng Z, Fear MW, Suk Choi Y, Wood FM, Allahham A, Mutsaers SE, Prele CM (2020) The extracellular matrix and mechanotransduction in pulmonary fibrosis. Int J Biochem Cell Biol 126:105802. https://doi.org/10.1016/j.biocel.2020.105802
Article CAS PubMed Google Scholar
Rosmark O, Ahrman E, Muller C, Elowsson Rendin L, Eriksson L, Malmstrom A, Hallgren O, Larsson-Callerfelt AK, Westergren-Thorsson G, Malmstrom J (2018) Quantifying extracellular matrix turnover in human lung scaffold cultures. Sci Rep 8(1):5409. https://doi.org/10.1038/s41598-018-23702-x
Article CAS PubMed PubMed Central Google Scholar
Decaris ML, Gatmaitan M, FlorCruz S, Luo F, Li K, Holmes WE, Hellerstein MK, Turner SM, Emson CL (2014) Proteomic analysis of altered extracellular matrix turnover in bleomycin-induced pulmonary fibrosis. Mol Cell Proteomics 13(7):1741–1752. https://doi.org/10.1074/mcp.M113.037267
Article CAS PubMed PubMed Central Google Scholar
Ba YD, Sun JH, Zhao XX (2020) Evogliptin attenuates bleomycin-induced lung fibrosis via inhibiting TGF-beta/Smad signaling in fibroblast. Eur Rev Med Pharmacol Sci 24(20):10790–10798. https://doi.org/10.26355/eurrev_202010_23439
Li A, Xiao X, Feng ZL, Chen X, Liu LJ, Lin LG, Lu JJ, Zhang LL (2020) Nagilactone D ameliorates experimental pulmonary fibrosis in vitro and in vivo via modulating TGF-beta/Smad signaling pathway. Toxicol Appl Pharmacol 389:114882. https://doi.org/10.1016/j.taap.2020.114882
留言 (0)